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Abstract
Single nucleotide polymorphisms (SNPs) close to the gain-of-function substitution, Asn(107)
Ile (rs324981, A>T), in Neuropeptide S Receptor 1 (NPSR1) have been associated with
asthma. Furthermore, a functional SNP (rs4751440, G>C) in Neuropeptide S (NPS) encodes
a Val(6)Leu substitution on the mature peptide that results in reduced bioactivity. We sought
to examine the effects of different combinations of these NPS and NPSR1 variants on down-
stream signaling and genetic risk of asthma. In transfected cells, the magnitude of NPSR1-
induced activation of cAMP/PKA signal transduction pathways and downstream gene expres-
sion was dependent on the combination of the NPS and NPSR1 variants with NPS-Val(6)/
NPSR1-Ile(107) resulting in strongest and NPS-Leu(6)/NPSR1-Asn(107) in weakest effects,
respectively. One or two copies of the NPS-Leu(6) (rs4751440) were associated with physi-
cian-diagnosed childhood asthma (OR: 0.67, 95%CI 0.49–0.92, p = 0.01) and together with
two other linked NPS variants (rs1931704 and rs10830123) formed a protective haplotype (p
= 0.008) in the Swedish birth cohort BAMSE (2033 children). NPS rs10830123 showed epis-
tasis with NPSR1 rs324981 encoding Asn(107)Ile (p = 0.009) in BAMSE and with the linked
NPSR1 rs17199659 (p = 0.005) in the German MAGIC/ISAAC II cohort (1454 children). In
conclusion, NPS variants modify asthma risk and should be considered in genetic association
studies of NPSR1 with asthma and other complex diseases.
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Introduction
Neuropeptide S (NPS) affects multiple neuroendocrine, behavioral, and inflammatory
responses via its G protein-coupled cell surface receptor NPSR1 (Neuropeptide S Receptor 1)
[1–4]. NPSR1 was identified as a susceptibility gene for asthma and related traits by positional
cloning and the associations of NPSR1 single nucleotide polymorphisms (SNPs) with asthma
have been replicated in ethnically diverse populations [5–12], and marginally supported by a
large-scale genome-wide association study (GWAS) [13]. In addition, NPSR1 SNPs have
shown genetic associations with other inflammatory phenotypes such as inflammatory bowel
disease [14] and rheumatoid arthritis [15, 16]. However, the NPSR1 locus has shown allelic het-
erogeneity with different markers (tag SNPs, intronic markers, and haplotypes) showing asso-
ciations depending on the study design and population being studied. We have previously
shown that several susceptibility alleles of low-to-moderate-effects in NPSR1 may modify the
asthma risk and show epistasis depending on the carrier status for variants in genes belonging
to common biological pathways [17]. These effects may not be uncovered by SNP arrays which
are suitable for detection of common polymorphisms but cannot detect the effects of less fre-
quent coding mutations and low frequency functional SNPs.
The functional NPSR1 SNP rs324981 (A>T), encoding a substitution of Asn(107)Ile in the
putative ligand-binding pocket of NPSR1 [5], has shown associations with neuropsychiatric
phenotypes, such as panic disorders [18–20], psychological stress [21], and fear responses [22,
23]. A GWAS on circadian sleep parameters found an association between rs324981 and regu-
lar bedtime [24] and another study showed that the same SNP was associated with sleep and
rest duration [25]. In cell models, the change of Asn(107) to Ile(107) results in 10-fold increase
in NPS-mediated intracellular signaling [26] and changes in genome-wide transcriptional pro-
files [27]. In addition, the NPSR1 SNP rs324981 has been associated with airway hyperrespon-
siveness to methacholine in a Chinese population [8]. Non-coding functional SNPs have also
been detected in NPSR1, for instance rs2530547 which affects luciferase expression in gene
reporter assays and NPSR1 mRNA levels in human leukocytes [27]. By changing the levels of
expression in this receptor, they may ultimately also affect signaling, and are hypothesized to
affect neuroinflammatory phenotypes [28]. Thereby associations with individual NPSR1 SNPs
needs to be evaluated in the context of gene-gene interactions because a combination of func-
tional polymorphisms may ultimately determine receptor properties and/or expression levels
[27].
A functional SNP rs4751440 in NPS encodes a Val(6)Leu substitution in the mature NPS
peptide that results in lower bioactivity [29]. We hypothesized that the interaction of func-
tional NPS and NPSR1 SNPs might lead to either strong or minimal downstream signaling
depending on the genotype combination on both loci. The aims of this study were: 1) To clar-
ify the potential functional crosstalk between NPS and NPSR1 variants; 2) to identify the
impact of putative NPS risk alleles on the susceptibility to asthma; and 3) to evaluate potential
gene-gene interaction effects (epistasis) between NPS and NPSR1 polymorphisms on asthma.
Results
Biological interaction of NPS and NPSR1 variants can lead to either
strong or minimal downstream signaling
NPS is known to activate NPSR1 by increasing cAMP production [30, 31]. To compare the
bioactivities of the two NPS variants, we measured the dose-responses of NPSR1-Ile(107) and
NPSR1-Asn(107) coding variants to either wildtype NPS-Val(6) or alternative NPS-Leu(6) in a
luciferase assay dependent on the activation of a cAMP-response element (CRE). This assay
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was used since elevation of the intracellular cAMP levels activates cAMP response element
binding protein (CREB) via phosphorylation of protein kinase A (PKA). Activated CREB
binds to CRE and induces the expression of downstream target genes of the cAMP/PKA sig-
naling pathway. Because of the low endogenous expression levels of NPSR1 in majority of the
available cell lines [26, 29], we first used HEK293 cells with forced NPSR1 expression as a
model for ligand-receptor interactions. This approach allowed comparisons between the pres-
ent and previous studies [26, 29]. HEK293 cells were transiently co-transfected with the two
NPSR1 variants along with a CRE-responsive firefly luciferase construct and a construct con-
stitutively expressing Renilla luciferase. Firefly and Renilla luciferase activity was measured 3 h
after stimulation with serial dilutions of NPS (10 pM-100 μM). As shown in Fig 1, wildtype
NPS—Val(6) peptide stimulated CRE—dependent luciferase activity at 50—fold lower con-
centrations than the NPS—Leu(6) peptide in NPSR1—Ile(107) cells (pEC 50: 8.4 ± 0.2 and
6.7 ± 0.2, p = 0.004, respectively), and at 15-fold lower concentrations in NPSR1—Asn(107)
cells (pEC 50: 6.1 ± 0.3 and 4.9 ± 0.1, p = 0.03, respectively).
The maximum of luciferase activity was ~2-fold in cells transfected with the NPSR1-Ile
(107) variant in comparison to the cells transfected with the NPSR1-Asn(107). Thus, the
magnitude of NPSR1-induced activation of CRE was markedly different depending on the
combination of the NPS and the NPSR1 variants resulting in either strong (NPS-Val(6)
and NPSR1-Ile(107)) or minimal (NPS-Leu(6) and NPSR1-Asn(107)) downstream signal
transduction.
The activation of CRE results in transcriptional changes of downstream target genes. To
examine whether the observed differences in the promoter activity also affected gene expres-
sion, we measured the effects of NPS variants on known NPSR1 downstream target genes [27,
32, 33]. NR4A1 (nuclear receptor subfamily 4, group A, member 1), FOS (FBJ murine osteosar-
coma viral oncogene homolog), and chemokine ligands CXCL2 and CCL20were selected as
they were among the most influenced genes after NPS stimulation and their expression also
differed between transcriptome comparisons of HEK293 cells expressing either NPSR1-Ile
Fig 1. NPS variants and CRE luciferase activity. Dose-response curves of NPS-Val(6) and NPS-Leu(6) (10 pM– 100 μM) based on the
cAMP response element (CRE) luciferase activity in human embryonic kidney epithelial (HEK293) cells transiently transfected with either
NPSR1-Ile(107) or NPSR1-Asn(107) coding variants. One representative experiment is shown. The CRE-driven luciferase activity is
expressed in mean arbitrary units ± SEM of triplicates 3 h after NPS stimulation.
https://doi.org/10.1371/journal.pone.0176568.g001
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(107) or NPSR1-Asn(107) [27]. In the present study, HEK293 cells transiently transfected with
either NPSR1-Ile(107) or NPSR1-Asn(107) coding variants were stimulated with 100 nM of
either NPS-Val(6) or NPS-Leu(6) for 1, 3, 6, and 24 h, and changes in gene expression were
analyzed with RT-PCR. In agreement with the results from the luciferase assay, NPS induced
stronger downstream signaling in cells expressing NPSR1-Ile(107) than in cells expressing
NPSR1-Asn(107), and wildtype NPS-Val(6) peptide was more potent than the NPS-Leu(6)
peptide. mRNA expression of NR4A1, FOS, and CXCL2 was induced 1 h after NPS stimulation
whereas the expression of CCL20was up-regulated at 3 h (Fig 2A).
Altered neuroinflammatory mechanisms have been implicated in allergic airway inflamma-
tion [34]. Because NPSR1 is expressed in neuroendocrine tissues [35–37], we used SH-SY5Y
neuroblastoma cells of neuroendocrine origin to validate the changes in gene expression
observed in HEK293 cells. SH-SY5Y cells stably overexpressing NPSR1-Ile(107) [17, 36] were
stimulated with either NPS-Leu(6) or NPS-Val(6) (0.0001–1 μM) for 3 h and the mRNA
expression of known downstream target genes in these cells [36] was detected using RT-PCR.
As expected, NPS stimulation increased the expression of NR4A1, FOS, EGR1 (early growth
response protein 1), and IER3 (immediate early response 3) in SH-SY5Y cells over-expressing
NPSR1-Ile(107) in a dose dependent manner (Fig 2B). Wildtype NPS-Val(6) peptide was
more potent than the NPS-Leu(6) peptide. These observations validated the results detected in
HEK293 cells in an independent cell line.
NPS rs4751440 encoding Leu(6) is protective for childhood asthma
Because the SNP rs4751440 (G/C) encoding for NPS-Val(6) and NPS-Leu(6) is common in
European and American mixed populations [29], and given its functional effects on NPSR1
signaling in cell assays, we hypothesized that this SNP might influence the genetic risk of
diverse disease traits including asthma. The rs4751440 Val(6)Leu and two other NPS SNPs
Fig 2. Real time RT-PCR analysis of NPSR1 downstream target genes. (A) Time-dependent mRNA expression of NR4A1, FOS, CXCL2, and CCL20
in human embryonic kidney epithelial (HEK293) cells transiently transfected with either NPSR1-Ile(107) or NPSR1-Asn(107) coding variants and
stimulated with either NPS-Val(6) or NPS-Leu(6) NPS (100 nM) for 1, 3, 6, and 24 h. (B) Dose-response curves of NR4A1, FOS, IER3, and EGR1 in
human SH-SY5Y stable cell line over-expressing NPSR1-Ile(107) stimulated with either NPS-Leu(6) or NPS V6 (0.0001–1 μM) for 3 h. The results are
presented as fold-changes in comparison to the unstimulated cells. GAPDH was used as the endogenous reference, and data are expressed as mean of
triplicate samples. The error bars represent 95% confidence intervals. In all experiments, results were calculated with the comparative Ct method.
https://doi.org/10.1371/journal.pone.0176568.g002
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(rs1931704 and rs10830123) were analyzed for associations with physician-diagnosed child-
hood asthma in the prospective Swedish birth-cohort BAMSE (n = 2033) [38, 39]. The SNPs
spanned a region of 11 kb on chromosome 10q26.2 and were in linkage disequilibrium (LD)
with each other (Fig 3A). The allele frequencies of the three NPS SNPs in cases and controls
and the results of the association tests with asthma are presented in S1 Table. Two NPS SNPs
(rs1931704 and rs4751440) in strong linkage disequilibrium (D’ = 0.99, r2 = 0.69) were signifi-
cantly associated with physician-diagnosed childhood asthma at age 8 years under dominant
(p = 0.01) and additive models (p = 0.03). For both NPS SNPs the effect was driven by a higher
frequency of the minor allele in the control group (Fig 3B). These results revealed that the
allele C in NPS rs4751440 encoding for Leu(6) is protective for asthma. The association
Fig 3. Location and block structure of three genotyped SNPs in the NPS gene. (A) The scale represents the relative positions of rs1931704 (G>A) in
the upstream regulatory region of NPS, followed by rs10830123 (G>C) in the intronic region and rs4751440 (G>C) in the coding region. Allele changes are
indicated by > and given on the positive chromosomal strand of the Human Reference Assembly. The arrow indicates NPS transcription from the positive
strand. (B) Effects of NPS SNPs on the risk of physician-diagnosed asthma in carriers of either one or two copies of the alternative allele. Bars represent 95%
confidence intervals (CI). OR: Odds Ratio. Given the allele and genotype frequencies, the dominant model which best fits the data is shown.
https://doi.org/10.1371/journal.pone.0176568.g003
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between NPS variants and asthma was also significant when comparing the haplotype frequen-
cies between asthmatic children and controls with a protective effect driven by the haplotype
AGC (p = 0.008) (Table 1). There were no significant associations between NPS SNPs and
atopic sensitization (data not shown).
Gene-gene interactions between NPS and NPSR1 variants
Based on the effects of the NPS SNP rs4751440 on genetic asthma risk and NPSR1 signaling,
we first tested genetic association of 29 NPSR1 SNPs with physician-diagnosed childhood
asthma in BAMSE (n = 2033), and then assessed epistasis between NPS and NPSR1. We
detected significant association between three NPSR1 SNPs (rs887020, rs2531840 and
rs11770777) with asthma (p<0.05) and confirmed that the functional rs324981 (T>A) en-
coding for NPSR1-Ile(107) and NPSR1-Asn(107) had no significant main effects at present
resolution (S2 Table). The next aim was to investigate if the effects of NPS SNPs (rs1931704,
rs10830123 and rs4751440) on the risk of asthma were modified by the carrier status of alleles
in the SNP rs324981 (A>T) encoding for NPSR1-Asn(107) and NPSR1-Ile(107), respectively,
or by other variants with previous evidence of putative functional effects in the NPSR1 gene.
We detected significant interaction between NPS SNP rs10830123 and NPSR1 rs324981 (inter-
action p value = 0.009). There were also significant interactions between NPS SNP rs10830123
with two additional NPSR1 SNPs (rs323922 and rs324384) in linkage disequilibrium with
NPSR1 rs324981 (Fig 4). A second region with significant interactions between NPS and
NPSR1 was detected between two SNPs in the NPSR1 promoter (rs2125404 and rs2168890)
and NPS SNP rs10830123 (Fig 4) and S3 Table.
We then explored the gene-gene interaction between NPS and NPSR1 SNPs in the MAGIC/
ISAAC cohort (n = 1454). NPS and NPSR1 SNPs did not show any significant main effects on
asthma risk in this dataset (data not shown). However, there was a significant interaction
between NPS rs10830123 and NPSR1 rs17199659 (p = 0.005) (Fig 4 and S3 Table). NPSR1
rs17199659 is in LD (D’ = 0.95, r2 = 0.19) with NPSR1 rs324981 encoding for NPSR1-Asn(107)
and NPSR1-Ile(107) and with rs324384, both showing significant gene-gene interactions in
BAMSE (Fig 4). These results suggested that the epistatic signal with NPS was driven by
genetic variants in the proximities of exon 3 and exon 4 in NPSR1.
Discussion
Previous studies have shown that some polymorphic variants in the genes encoding NPS and
NPSR1 have functional effects in modifying peptide bioactivity or receptor signaling efficacy
[26, 29]. However, no study has yet analyzed the functional outcomes of the different combina-
tions of coding NPS and NPSR1 variants upon ligand/receptor interactions. This is of critical
relevance, because coding SNPs such as NPS rs4751440 or NPSR1 rs324981 are commonly
observed in humans, and cells in any given individual will carry one out of nine alternatives of
Table 1. Haplotype association of NPS polymorphisms with asthma at 8 years.
Haplotype rs1931704 (G>A) rs10830123 (G>C) rs4751440 (G>C) Frequency (controls) Frequency (asthmatics) OR 95%CI (p-value)
1 G G G 0.70 0.76 1.0 -
2 A G C 0.14 0.10 0.71 (0.53–0.94) 0.01
3 A C G 0.11 0.10 0.87 (0.65–1.16) 0.3
Global haplotype association p-value = 0.0077
Allele changes are indicated by > and given on the positive chromosomal strand of the Human Reference Assembly.
https://doi.org/10.1371/journal.pone.0176568.t001
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genotype combinations at these two loci. We examined the effects of the peptides NPS-Val(6)
and NPS-Leu(6) on the signal transduction of NPSR1, expressed as two variants with different
signaling efficacy (NPSR1-Ile(107) and NPSR1-Asn(107)). Our results clearly showed that the
magnitude of NPSR1 signaling (as determined by reporter gene assays) and expression levels
of downstream genes was dependent on the combination of NPS and NPSR1 variants, with the
highest induction obtained upon stimulation of NPSR1-Ile(107) overexpressing cells with
NPS-Val(6), and the lowest induction obtained with the combination of NPSR1-Asn(107) and
NPS-Leu(6). Genetic association analyses further suggested epistasis between NPS and NPSR1
variants with the most significant interactions being centered to the region of NPSR1 rs324981
encoding for NPSR1-Ile(107) and NPSR1-Asn(107).
A key strength of this study is the use of robust in vitro cell assays that allowed us to dissect
the functional effects of coding NPS/NPSR1 variants on receptor signaling and downstream
gene expression. Our cell assays confirmed that stimulation of cells transfected with either
NPSR1-Asn(107) or NPSR-Ile(107) with the wildtype NPS-Val(6), induced CRE activity as
described previously [26, 27]. Reinscheid et al. [26] have previously shown that upon stimula-
tion with NPS-Val(6), stable HEK293 cell lines expressing NPSR1-Asn(107) and CRE-lucifer-
ase reporter gene displayed an induction of luciferase activity with a mean EC50 of 45 nM,
which was roughly 10-fold lower than in this study (428 nM). For NPSR1-Ile (107), the stimu-
lation with NPS-Val(6) produced an increase in reporter gene expression with an EC50 of 0.6
nM, which was 10-fold lower than what we observed (4.8 nM) [26]. The differences could be
explained by the *20-fold lower magnitude of reporter gene induction in transiently trans-
fected cells compared with stable clones [26]. In agreement with our study, the maximum of
reporter gene expression in HEK293 cells transiently transfected with NPSR-Ile (107) was
*2-fold higher than in cells expressing NPSR1-Asn(107), indicating an increase in agonist
efficacy. Another previous study observed EC50 values of 37 nM and 586 nM for NPS-Val(6)
Fig 4. Gene-gene interactions between NPSR1 and NPS. Location of six NPSR1 SNPs with significant interactions with NPS rs10830123 in the
multiplicative model for epistasis in connection with their p-value for interaction and linkage disequilibrium. The most significant interaction signals in
BAMSE (green) and MAGIC/ISAAC (orange) are marked in bold. Statistics on LD between the functional rs324981 and other interacting SNPs are
provided as D’ and r2.
https://doi.org/10.1371/journal.pone.0176568.g004
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and NPS-Leu(6), respectively, in CRE-luciferase activity 18 h after stimulation of HEK293 cells
transiently transfected with NPSR1-Asn(107) [29]. Overall, our results were in line with these
previous observations, and methodological issues, such as differences in NPS incubation time
and transfection efficiency, might well explain the differences observed.
Our genetic analyses in the birth cohort BAMSE uncovered the association between NPS
rs4751440 and the presence of asthma by 8 years. Another NPS SNP (rs10830123) showed bor-
derline association with asthma, and formed a protective haplotype with NPS rs1931704 and
NPS rs4751440. The protective effect of the minor allele C in NPS rs10830123 became signifi-
cant only in the presence of two copies of rs324981 (TT) encoding NPSR1-Ile(107). In the rep-
lication cohort, NPS rs10830123 showed interaction with NPSR1 rs17199659 which is in
linkage disequilibrium with rs324981 and rs324384. Due to the LD, NPS rs10830123 can be
used as a proxy for the effects of NPS rs4751440 (Fig 4). Although the latter had significant
main effects on asthma risk and proved to be functional in the cell assays, a lower frequency of
informative GC heterozygotes in the patient group could have influenced the power to detect
gene-gene interactions with NPSR1. Indeed, 24% of non-asthmatic children were heterozygous
for NPS rs4751440 and there was a low frequency of CC carriers in the cohorts with only 2% of
children being homozygous (CC) for NPS-Leu(6). This was in line with previous findings sug-
gesting that 22% of Europeans are heterozygous for NPS rs4751440 [29]. Nevertheless, it is
consistent in BAMSE and MAGIC/ISAAC that the most significant interaction was centered
to the region of NPSR1 rs324981 encoding for NPSR1-Ile(107) and NPSR1-Asn(107). Alto-
gether, our results supported the role of the NPS/NPSR1 pathway in asthma and the notion of
a “combinatory effect”, in which the phenotype is driven by the interaction of several variants
of moderate effects that coincide and affect a biological pathway [17].
In BAMSE, the NPS rs10830123 also showed significant interactions with two SNPs located
in the upstream region of NPSR1 (rs2125404 and rs2168890). These were in LD with NPSR1
rs2530547 previously found to affect NPSR1 mRNA levels in human leukocytes [27] and with
three SNPs affecting NPSR1 mRNA expression in cerebellum (rs2530549, rs2530550, and
rs2530566) according to the Genotype-Tissue Expression database (http://gtexportal.org/
home/gene/NPSR1). Furthermore, a bioinformatic analysis on the transcription binding sites
that are created or destroyed by the five NPSR1 SNPs implicated in the gene-gene interactions
with NPS (S3 Table) revealed that the change of cytosine (C) to guanine (G) in NPSR1
rs323922 is predicted to affect the binding site of V$NBRE/NBRE.01 related to the monomers
of the nur subfamily of nuclear receptors (NR4A1-3, also known as nur77, nurr1, nor-1, S4
Table).
Previous transcriptome studies in HEK293 cells [32, 33] and SH-SY5Y cells [36] overex-
pressing NPSR1-Ile(107) revealed downstream target genes with NR4A1 and FOS being
among the most affected transcription factors. In our cells assays, the magnitude of the mRNA
expression of NR4A1 was clearly dependent on the combination of NPS and NPSR1 variants
(Fig 2). NR4A1 is expressed in lymphocytes upon stimulation and is anti-inflammatory [40–
42]. NR4A1 has been recently described as a key regulator of catecholamine production by
macrophages linking sympathetic stress response and inflammation [43]. The hypothesis of a
regulatory loop influenced by particular combinations of NPS/NPSR1 variants is further sug-
gested by the up-regulation of the transcription factor FOS in cells expressing NPSR1-Ile(107)
upon stimulation with NPS-Val(6) and the fact that the promoter region of NPSR1 is known to
contain FOS binding motifs [28]. The upregulation of NR4A1and FOS induced by the combi-
nation of NPS-Val(6) and NPSR1-Ile(107) is anticipated not only to interact in a feedback loop
with their regulatory elements in NPSR1 but also to regulate a number of other target genes
including those involved in immune responses. For instance, the levels of serum pro-inflam-
matory cytokines could be activated by both central and peripheral administration of NPS in
Neuropeptide S and asthma
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pigs [44], and NPS has shown direct effects on phagocytosis [45] [46] and chemotaxis [47]
[48]. Further insights to immune responses are suggested by the upregulation of CXCL2 and
CCL20 encoding chemokine receptors ligands (Fig 2).
The findings of significant epistatic signals implicating coding and non-coding variants
allowed us to suggest a model in which the divergent biological outcomes driven by coding
variants in NPS and NPSR1 do occur at the level of ligand/receptor interactions but also impli-
cate the effects of polymorphic variants in non-coding regions and the cross-talk of regulatory
elements in diverse loci (Fig 5). We must emphasize that the sample size analyzed in this study
is underpowered to detect epistatic effects. However, the facts that the interaction signals in
the two independent cohorts were narrowed to the same gene regions (Fig 4) and a recent
meta-analysis on a larger dataset such as GABRIEL [49] confirmed the interaction signals that
we originally identified in this population between NPSR1 and RORA [17], suggest that the
interactions between NPS and NPSR1 may occur and are detectable at present resolution.
Additional studies using larger sample sizes more suitable to test for epistasis are needed to
confirm these findings.
In conclusion, our results supported the association of the NPS/NPSR1 pathway with
asthma and provided a molecular framework on how the different NPS and NPSR1 variants
interact in asthma. This study provides the basis for further investigations analyzing the inter-
acting effects of NPS/NPSR1 variants in many other phenotypes and also support that poly-
morphic variants in NPS should be taken into account when analyzing the effects of NPSR1
SNPs. Such gene-gene interactions as observed here may dilute or dampen association signals
in genetic association studies.
Materials and methods
Ethics statement
All methods were carried out in accordance with relevant guidelines and regulations and the
study followed the ethical principles for medical research stated in the Declaration of Helsinki.
All of the experimental protocols were approved by the Swedish Regional Ethics Committee at
Karolinska Institutet, Stockholm, Sweden in the BAMSE cohort (Dnr: 01–478 and 02–420)
and by the Ethic Committee of the Bavarian Medical Council for MAGIC/ISAAC (approval
nr. 01218). Written informed consent was obtained from parents/guardians on behalf of all
child participants.
Cell culture and NPS stimulations
Human embryonic kidney cells (HEK293) were cultured in MEM+GlutaMAX-1 medium
(Gibco/Invitrogen) supplemented with 10% fetal calf serum (FCS) (Biosera), 1% sodium pyru-
vate, 1% non-essential amino acids and 1% penicillin/streptomycin (Gibco/Invitrogen). Cells
were kept at 37˚C in a humidified 5% CO2 incubator. The cells were transiently transfected
(Lipofectamin™2000 Reagent, Invitrogen, Carlsbad, USA) with equal amounts of pCMV-
NPSR1-Ile(107)or NPSR1-Asn(107) [27] in a ratio of 1:2 (DNA:Lipofectamin), and stimulated
with NPS 24 h after transfection. The cells were stimulated with either 100 nM NPS-Val(6)
(SFRNGVGTGMKKTSFQRAKS) or 100 nM NPS-Leu(6) (SFRNGLGTGMKKTSFQRAKS)
(both from Proteogenix, France) for 1, 3, 6, and 24 h. The HEK293 cell line was chosen for
ligand-receptor studies because it is a well-established model for addressing numerous
questions in basic biology and is easy to transfect and amenable of stringent quantitative
assessment.
The stable NPSR1-A-GFP expressing SH-SY5Y cells were engineered and cultured as
described before [17]. For gene expression studies, the SH-SY5Y cells over-expressing NPSR1
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were seeded at 0.5×106 cells/ml to 6-well plates. After 24 h, fresh cell media was added, and the
cells were incubated with a dilution series of either NPS-Val(6) or NPS-Leu(6) (0.0001–10 μM)
for 3 h. The changes in gene expression were analyzed with real-time PCR (RT-PCR).
Fig 5. A schematic model on the functional crosstalk between NPS and NPSR1. (A) The non-synonymous NPS-Leu(6) substitution
affects NPS bioactivity. Depending on the NPSR1-Asn(107) or NPSR1-Ile(107) genotype, binding of NPS can lead to strong or minimal
signaling as well as differential expression of downstream target genes such as the transcription factors FOS and NR4A1. (B) Two
hypothetical mechanisms in which the differential expression of FOS and NR4A1 can modulate the outcomes of the NPS/NPSR1 pathway.
FOS and NR4A1 bind to their regulatory elements in NPSR1 creating a feed-back loop that affect cell surface expression of NPSR1 and
availability, and also, affect a number of other downstream genes that modulate neuroinflammation and ultimately asthma risk.
https://doi.org/10.1371/journal.pone.0176568.g005
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Luciferase assays
For pharmacokinetic studies, HEK293 cells in 24-well plates were co-transfected with 700 ng
of NPSR1 cDNA expression vectors specific for different coding variants and 50 ng each of
cAMP response element (CRE) Firefly Luciferase reporter vector and CMV Renilla Luciferase
reporter plasmid (purchased as pre-formulated mix from SABiosciences, Frederick, MD,
USA). The day after transfection the cells were stimulated for 3 h with NPS at various concen-
trations (range 10 pM– 100 μM) before preparation of total cell lysates. In all reporter assays,
Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer’s instructions, in a Microplate Reader Infinite 200 (Tecan,
Ma¨nnedorf, CH). Experiments were performed three times in triplicates, and Firefly Luciferase
activity was expressed in arbitrary units relative to the cells transfected with the vector without
NPS stimulation, after normalization for transfection efficiency based on values obtained for
Renilla Luciferase. The concentration-response curve values for pEC50, and Emax were calcu-
lated using nonlinear regression analysis, and the data are presented as means ± SE. Statistical
analysis was performed using one-way ANOVA followed by unpaired t-test for comparison
between two groups. For the analyses, GraphPad Prism 5.01 (GraphPad Software, San Diego,
CA) was used.
Real-time RT-PCR
Total cellular RNA was isolated with the RNAeasy Mini Kit (Qiagen, Hilden, Germany).
Reverse transcription was performed with TaqMan reverse transcription reagents (Applied
Biosystems, Rotkreuz, Switzerland) using random hexamer primers according to the manufac-
turer’s protocol.
The mRNA expression was measured with qRT-PCR using either SYBR Green (for
NR4A1, FOS, IER3, and EGR1, the primer sequences are given in S5 Table) or TaqMAN assay
(Hs00601975 for CXCL2 Hs00601975, Hs01011368 for CCL20, Hs01036497 for NPSR1 and
Pre-Developed TaqMAN Assay Reagents, Part No. 4310884 for GAPDH; Applied Biosystems).
The PCR assays were performed in a total volume of 10 μl, using 7500 Fast Real-Time
PCR system (Applied Biosystems) with the following reaction conditions: 50˚C for 2 min and
94˚C for 10 min; followed by 45 cycles of 92˚C for 14 s and 1 min at 60˚C. A dissociation stage
was added to the SYBR Green reactions to confirm primer specificity. Results are shown as rel-
ative expression compared with unstimulated cells and GAPDH (Applied Biosystems) was
used as an endogenous control. Samples were normalized to GAPDH (in SH-SY5Y cells) or
to GAPDH and NPSR1 in order to control for the efficiency of the transient transfections (in
HEK293 cells). The variation in NPSR1 expression (Ct values) between cells transfected with
the NPSR1-Asn(107) and NPSR1-Ile(107) was within one cycle. Expression levels of mRNA in
each sample were determined by the comparative CT method of relative quantification, and
expressed in fold-changes relative to the chosen reference sample.
Study populations
Genetic association analyses were conducted in the prospective Swedish birth-cohort BAMSE
(Children Allergy Milieu Stockholm an Epidemiological study), which is an unselected, popu-
lation-based Swedish birth cohort originally designed to assess risk factors for allergic diseases
in childhood. This prospective study of 4,089 children has been described in detail elsewhere
[38, 39]. At age 8, all children were invited to clinical testing and blood samples were obtained.
After exclusion of samples with too little blood, incomplete questionnaire data, or lack of
parental consent to genetic analysis there were 2033 samples with DNA extracted for genetic
studies (of which 262 were asthmatics). All samples were analyzed coded. The study was
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approved by the Regional Ethical Committee of Karolinska Institutet, Stockholm, Sweden.
Written informed consent was obtained from the parents and/or legal guardians.
Replication studies were carried out in 1454 children from the Multicenter Asthma Genetic
in Childhood (MAGIC) study (mean age 11 y) and the cross sectional International Study of
Asthma and Allergies in Childhood phase II (ISAAC II) study (age 9–11 y) [50–52]. From
both populations, all samples which had been part of the first GWAS on asthma [50] and for
which we had imputation data available were selected for this study. After quality control
(QC), 1,454 samples (763 asthmatics and 683 controls) remained for analysis. All study meth-
ods were approved by the local ethics committees and written informed consent was obtained
from all parents of children included in this study. To control for population stratification, all
children were of German descent. Considering that previous studies have detected only mar-
ginal genetic differences between Swedes and Germans, and that GWAS data supported that
within Europe, Germans and Swedes are most closely related [53], it can be assumed that the
Swedish BAMSE and the German ISAAC/MAGICS were comparable.
Phenotype assessment
Information on the clinical outcomes was obtained from questionnaires filled out by the
parents, except for atopic sensitization which was assessed from plasma samples. In BAMSE,
Asthma ever up to 8 years was defined as a physician-diagnosed asthma between 3 mo after
birth and up to 8 y of age [54]. Atopic sensitization was considered present if a child had levels
of allergen-specific IgE>0.35 kU/L to Phadiatop, a mixture of cat, dog, horse, birch, timothy,
mugwort, Dermatophagoides pteronyssinus, and Cladosporium allergens at 8 y of age (Immuno-
CAP, Thermo Fisher Scientific, Phadia AB, Uppsala, Sweden).
In MAGIC, the assessed variables included asthma and allergy, which were diagnosed by a
pediatric pulmonologist according to clinical guidelines and objective measures such as lung
function tests, clinical examination, and allergy testing [51, 55]. In ISAAC II, children were
classified as having asthma if parents reported a physician’s diagnosis of asthma at least once,
or of spastic or asthmatic bronchitis more than once in self-administered questionnaires [56,
57]. The populations of the Swedish BAMSE and the German ISAAC/MAGICS are assumed
to be comparable because in both, the definition of the phenotype”asthma” was based on a
physician-diagnosis and the age range of the children was comparable (8 years in BAMSE vs.
10 years in ISAAC/MAGICS) [58].
SNP selection, genotyping and quality control
In BAMSE the NPS and NPSR1 polymorphisms were genotyped by using the iPLEX chemistry
on the SEQUENOM platform at the Mutation Analysis Facility (Karolinska Institutet), with
the exception of rs4751440 which was genotyped by a TaqMan SNP Genotyping Assay in an
ABI Prism 7500 Fast Sequence Detection System (Applied Biosystems) according to manufac-
turer’s instructions. Primers for multiplex PCR and extension reactions were designed by the
SpectroDesigner software (Sequenom GmbH, San Diego, CA, USA) and are available on
request. Each assay was validated using 24 unrelated Caucasians and 3 CEPH DNA samples as
well as 14 trios from the CEU population. Success rate for genotyping was 98.8%. In the
MAGIC/ISAAC study, NPS and NPSR1 SNPs were genotyped by the Illumina Sentrix Human-
Hap300 BeadChip as previously described [50]. The NPS gene spans a region of 3.3 kb on
chromosome 10q26.2 whereas the NPSR1 gene spans over ~220 kb of genomic DNA on chro-
mosome 7p14. The SNPs included in this study were selected based on their effects on protein
function (e.g. variants encoding for NPS-Val(6)Leu and NPSR1-Asn(107)Ile); previous reports
of association with asthma in children from BAMSE [6, 17] and other populations [5–12]; and
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by their functional [27] and tagging properties [17, 19, 28]. We analyzed 3 NPS SNPs
(rs1931704, rs10830123 and rs4751440 Val(6)Leu), 29 NPSR1 SNPs in the BAMSE cohort [17,
19], and 23 NPSR1 SNPs in MAGIC/ISAAC [50]. The discrepancy in the number of NPSR1
SNPs was due to the fact that some SNPs genotyped in BAMSE were not present in the array.
Genotype frequencies for all SNPs agreed with the expectations under Hardy-Weinberg
equilibrium.
Genetic association tests
Genetic association tests were conducted using Plink (version 1.07, http://pngu.mgh.harvard.
edu/purcell/plink) using the commands—assoc and—model. The comparison of allele fre-
quencies between cases and controls were done by χ2 and Fisher’s exact test. Full model associ-
ations were evaluated using the Cochran-Armitage trend test, and genotypic, dominant and
recessive models. The genotypic and dominant/recessive tests were only conducted if there
was a minimum number of five observations per cell either in the 2-by-3 or 2-by-2 tables.
Since we tested 32 individual SNPs it was expected at least 1.6 SNPs to be significant (p< 0.05)
due to chance. Epistasis was evaluated using the—epistasis command in PLINK. All pairwise
SNP combinations were tested in the case-control datasets. Allelic by allelic epistasis between
NPS and NPSR1 SNPs were calculated by logistic regression. The allele dosage of each SNP (A
and B) was modeled in the form of Y ~ β0 + β1.A+ β2.B + β3.AB + e and the test for interaction
based on the coefficient β3. In the equation, Y represents the presence of asthma as a function
of the intercept (β0) and the coeffients of the different alleles, and e the residual error.
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